|
Welcome
|
|
11 October 2008
|
|
|
| home | my details | ISRCTN Register | mRCT | UKCTG | links | information | news |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
| [ ...Back to search results ] | [ Print-friendly version ] |
| Randomised controlled trial of 6-Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection |
| Source of record | UK Clinical Trials Gateway |
| ISRCTN | ISRCTN89489788 |
| Date ISRCTN assigned | 15/06/2007 |
| Local reference number(s) | G0600329 |
| Public title | Randomised controlled trial of 6-Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection |
| Scientific title | |
| Acronym | TOPPIC (Trial Of Prevention of Post-operative Crohn's disease) |
| Disease/condition/study domain | Crohn's disease |
| Study hypothesis | Therapy with 6 MP prevents or delays post-operative recurrence of Crohn's disease. |
| Design/methodology | Multi-centre double blind, randomised, placebo-controlled trial. |
| Research ethics review | Scotland A Research Ethics Committee, NHS Scotland. Date of approval: 14/08/2007 (REC Ref No: 07/MRE00/74) |
| Countries of trial | United Kingdom |
| Participants - inclusion criteria | 1. Male or female, at least 16 years of age in Scotland and 18 years of age in England and Wales 2. Established diagnosis of Crohn¿s disease 3. Ileocolonic resection within 3 months 4. Able to start oral nutrition and medication within the first 2 postoperative weeks 5. Normal or heterozygous Thio Purine Methyl-Transferase (TPMT) genotype 6. No more than 100 cms of fixed small bowel resected in total. Previous ileocolonic resection is acceptable 7. Able to provide written informed consent prior to screening and to comply with the requirements of the study protocol |
| Participants - exclusion criteria | 1. Pregnancy or breast feeding 2. Hypersensitivity or intolerance to 6MP or pancreatitis associated with azathioprine 3. Receiving an experimental treatment for Crohn¿s disease in the 4 weeks prior to study entry 4. Known to require further surgery at study entry 5. Presence of stoma 6. Significant renal or hepatic dysfunction, clinically important lung disease 7. Systemic infection including hepatitis C, HIV and active tuberculosis (TB) 8. A diagnosis of indeterminate colitis or ulcerative colitis 9. A history of illicit drug or alcohol abuse in the 1 year prior to study entry 10. History of cancer - excluding basal cell carcinoma treated more than 5 years previously and in-situ tumours 11. Presence of a medical or psychiatric condition, disease or laboratory abnormality that in the opinion of the PI may place the subject at unacceptable risk during the study 12. Homozygous deficient for TPMT 13. Initiation of the following drugs during the study is not allowed: corticosteroids (it is expected that patients may be on corticosteroids at entry. Doses will be tapered according to local protocols), anti-tumour necrosis factor, azathioprine, methotrexate, antibiotics (for a duration of >10 days), non steroidal anti-inflammatory drugs |
| Patient information material | |
| Anticipated start date | 01/10/2007 |
| Anticipated end date | 30/09/2013 |
| Status of trial | Ongoing |
| Target number of participants | 234, recruited over 3 years. |
| Interventions | Patients randomised to treatment with 6MP or matching placebo. 6MP will be given at a dose of 1 mg per kg body weight per day, rounded to the nearest 25 mg, for 3 years or until study drug is permanently discontinued. Safety monitoring of 6MP will be performed continuously throughout the trial, involving full blood count and liver function tests at appropriate intervals |
| Primary outcome measure(s) | Post-operative recurrence of Crohn¿s disease requiring anti-inflammatory rescue therapy and time of recurrence. |
| Secondary outcome measure(s) | 1. The need for a second operation to remove recurrent Crohn¿s disease from the anastomotic site 2. Changes in quality of life scores (assessed at 4 weeks [baseline / randomisation], 17 weeks, 1 year, 2 and 3 years using Inflammatory Bowel Disease Questionnaire [IBDQ], Medical Outcome Survey Short Form 36 [SF-36] and EQ-5D) 3. Endoscopic recurrence of Crohn¿s disease (assessed at 1 year and 3 years) 4. Relation of faecal calprotectin to time of disease recurrence 5. Relation of drug metabolite levels to time of disease recurrence 6. Exploratory analyses of clinical, genetic and serological markers for predicting disease recurrence |
| Sources of funding | Medical Research Council (Grant No: G0600329) |
| Sponsor name | University of Edinburgh, Lothian Health Board, University Hospitals Division (UK) |
| Sponsor details | Marise Bucukoglu Clinical Trials & Research Governance Manager College of Medicine & Veterinary Medicine The Queen's Medical Research Institute The University of Edinburgh Edinburgh United Kingdom EH16 4TJ |
| Contact name | Prof Jack Satsangi |
| Contact details | Professor of Gastroenterology Department of Gastrointestinal Medicine Western General Hospital Crewe Road South Edinburgh United Kingdom EH4 2XU |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN89489788 |
| Date last extracted from ISRCTN register | 17/04/2008 |
|
|
|
| terms & conditions | privacy statement | © Current Controlled Trials Ltd | |
|
|
|
|